Dosing recommendations vary based on the clinical indication and should follow UK guidance
Allison Institute, Scientific Advisory Board, The University of Texas MD Anderson Cancer Center, 2023 - Present Co-Chair, Colorectal Cancer Alliance, The University of Texas MD Anderson Cancer Center, 2023 - Present Member, AJCC 9th Edition Staging Manual, The University of Texas MD Anderson Cancer Center, 2022 - Present Chair of Search Committee, Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, 2022 - 2023 Chair, INTERCEPT Program Steering Committee, The University of Texas MD Anderson Cancer Center, 2021 - Present Member, Institutional Tissue Bank Internal Advisory Committee, The University of Texas MD Anderson Cancer Center, 2021 - Present Member, Merck / MD Anderson GI collaboration: Joint Steering Committee, The University of Texas MD Anderson Cancer Center, 2021 - Present Member, TRIUMPH Committee, The University of Texas MD Anderson Cancer Center, 2021 - Present Member, EORTC Translational Research Advisory and Protocol Review Committee, The University of Texas MD Anderson Cancer Center, 2021 - 2024 Chair, System Biology Search Committee, The University of Texas MD Anderson Cancer Center, 2021 - 2022 Member, Research Leadership Team, The University of Texas MD Anderson Cancer Center, 2020 - Present Member, MDACC-BI Joint Steering Committee, The University of Texas MD Anderson Cancer Center, 2020 - Present Member, Research and Academics Informatics, The University of Texas MD Anderson Cancer Center, 2020 - Present Co-Leader, Clinical Trial Management System Executive Committee, The University of Texas MD Anderson Cancer Center, 2020 - 2024 Board Member, ACCRU Group, The University of Texas MD Anderson Cancer Center, 2020 - 2024 Co-Leader, Natera/MD Anderson Alliance, Joint Steering Committee, The University of Texas MD Anderson Cancer Center, 2019 - 2022 Chair, Surgical Oncology Search Committee, The University of Texas MD Anderson Cancer Center, 2019 - 2020 Co-Leader, Lilly Oncology/MD Anderson Alliance Joint Steering Committee, The University of Texas MD Anderson Cancer Center, 2018 - 2024 Co-Leader, Astellas / Joint Steering Committee, The University of Texas MD Anderson Cancer Center, 2018 - 2024 Member, Guardant Health / MD Anderson Alliance Joint Steering Committee, The University of Texas MD Anderson Cancer Center, 2017 - Present Co-Leader, EMD Serono / MD Anderson Alliance, Joint Steering Committee, The University of Texas MD Anderson Cancer Center, 2017 - 2024 Member, Scientific Advisory Board of the K.G
Inorg Chim Acta 106:181186
Azalanostat (RS-21607), an imidazole derivative, inhibited cholesterol synthesis in HepG2, fibroblasts, and rodent hepatocytes and holds potential in atherosclerosis prevention [101]
Atherosclerosis 217 (1), 240248
Most trial data shows anxiety resolves after dose stabilization, suggesting a temporary adjustment rather than a permanent effect
